Australia markets closed

G1 Therapeutics, Inc. (G1H.F)

Frankfurt - Frankfurt Delayed price. Currency in EUR
Add to watchlist
3.9040+0.0260 (+0.67%)
As of 08:00AM CEST. Market open.
Currency in EUR

Valuation measures4

Market cap (intra-day) 206.12M
Enterprise value 189.32M
Trailing P/E N/A
Forward P/E N/A
PEG ratio (5-yr expected) N/A
Price/sales (ttm)2.59
Price/book (mrq)7.90
Enterprise value/revenue 2.25
Enterprise value/EBITDA -10.49

Trading information

Stock price history

Beta (5Y monthly) 1.70
52-week change 349.20%
S&P500 52-week change 325.59%
52-week high 34.4180
52-week low 31.0350
50-day moving average 33.5751
200-day moving average 32.4198

Share statistics

Avg vol (3-month) 3799
Avg vol (10-day) 3N/A
Shares outstanding 552.28M
Implied shares outstanding 652.93M
Float 843.93M
% held by insiders 110.81%
% held by institutions 128.87%
Shares short 4N/A
Short ratio 4N/A
Short % of float 4N/A
Short % of shares outstanding 4N/A
Shares short (prior month ) 4N/A

Dividends & splits

Forward annual dividend rate 4N/A
Forward annual dividend yield 4N/A
Trailing annual dividend rate 30.00
Trailing annual dividend yield 30.00%
5-year average dividend yield 4N/A
Payout ratio 40.00%
Dividend date 3N/A
Ex-dividend date 4N/A
Last split factor 2N/A
Last split date 3N/A

Financial highlights

Currency in USD.

Fiscal year

Fiscal year ends 31 Dec 2023
Most-recent quarter (mrq)31 Mar 2024

Profitability

Profit margin -36.40%
Operating margin (ttm)-62.50%

Management effectiveness

Return on assets (ttm)-10.81%
Return on equity (ttm)-84.13%

Income statement

Revenue (ttm)84.04M
Revenue per share (ttm)1.62
Quarterly revenue growth (yoy)11.80%
Gross profit (ttm)N/A
EBITDA -22.33M
Net income avi to common (ttm)-30.59M
Diluted EPS (ttm)-0.5600
Quarterly earnings growth (yoy)N/A

Balance sheet

Total cash (mrq)65.19M
Total cash per share (mrq)1.25
Total debt (mrq)47.09M
Total debt/equity (mrq)169.76%
Current ratio (mrq)2.94
Book value per share (mrq)0.53

Cash flow statement

Operating cash flow (ttm)-18.18M
Levered free cash flow (ttm)-4.94M